Alimera Sciences (Alimera Sciences) Cash, Cash Equivalents, Marketable Securities

: $12.06 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

Alimera Sciences's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($18.78 Mil) to Sep. 2023 ($8.29 Mil) but then increased from Sep. 2023 ($8.29 Mil) to Dec. 2023 ($12.06 Mil).

Alimera Sciences's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($16.51 Mil) to Dec. 2022 ($5.27 Mil) but then increased from Dec. 2022 ($5.27 Mil) to Dec. 2023 ($12.06 Mil).

Alimera Sciences Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Alimera Sciences's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

9.43

11.21

16.51

5.27

12.06

Alimera Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															5.27	13.09	18.78	8.29	12.06

Alimera Sciences Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Alimera Sciences (NAS:ALIM) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Alimera Sciences Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Alimera Sciences (Alimera Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

ASZ1:Germany

Address

6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005

Website

https://www.alimerasciences.com

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Executives

Margaret Pax	director	6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005
John Snisarenko	director	C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Pizzo Peter J. Iii	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Erin Parsons	director	97 WILLISTON RD, BROOKLINE MA 02445
Caligan Partners Lp	10 percent owner	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Ross D Demont	director	51 PICKWICK ROAD, NEWTON MA 02465
C. Daniel Myers	other: Chairman Emeritus	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
David Edward Johnson	10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
Velan Capital Master Fund Lp	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Adam Morgan	director	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Spv I Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Balaji Venkataraman	10 percent owner	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076